CorMedix Inc. (NYSEAMERICAN:CRMD) CFO Robert W. Cook bought 52,083 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were bought at an average price of $0.48 per share, with a total value of $24,999.84. Following the transaction, the chief financial officer now owns 102,083 shares of the company’s stock, valued at approximately $48,999.84. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of CorMedix Inc. (CRMD) traded down $0.01 during trading hours on Thursday, hitting $0.56. 729,869 shares of the company were exchanged, compared to its average volume of 678,664. CorMedix Inc. has a 12-month low of $0.32 and a 12-month high of $2.48.
Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in CorMedix by 3.0% during the second quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock valued at $518,000 after purchasing an additional 35,148 shares during the last quarter. Susquehanna International Group LLP lifted its position in CorMedix by 11,785.4% during the second quarter. Susquehanna International Group LLP now owns 2,067,973 shares of the biotechnology company’s stock valued at $886,000 after purchasing an additional 2,085,670 shares during the last quarter. Elliott Management Corp lifted its position in CorMedix by 177.8% during the second quarter. Elliott Management Corp now owns 4,166,868 shares of the biotechnology company’s stock valued at $1,785,000 after purchasing an additional 2,666,668 shares during the last quarter. Finally, Sabby Management LLC bought a new position in CorMedix during the second quarter valued at $1,818,000.
CorMedix Company Profile
CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.